Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.

Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer that is difficult to treat due to its resistance to both radiation and chemotherapy. This resistance is largely due to the unique biology of GBM cells, which can evade the effects of conventional treatments through mechanisms such as increased resistance to cell death and rapid regeneration of cancerous cells. Additionally, the blood–brain barrier makes it difficult for chemotherapy drugs to reach GBM cells, leading to reduced effectiveness. Despite these challenges, there are several treatment options available for GBM. The standard of care for newly diagnosed GBM patients involves surgical resection followed by concurrent chemoradiotherapy and adjuvant chemotherapy. Emerging treatments include immunotherapy, such as checkpoint inhibitors, and targeted therapies, such as bevacizumab, that attempt to attack specific vulnerabilities in GBM cells. Another promising approach is the use of tumor-treating fields, a type of electric field therapy that has been shown to slow the growth of GBM cells. Clinical trials are ongoing to evaluate the safety and efficacy of these and other innovative treatments for GBM, intending to improve with outcomes for patients.

Breast cancer is a heterogeneous disease with different molecular subtypes. Breast cancer is the second leading cause of mortality in woman due to rapid metastasis and disease recurrence. Precision medicine remains an essential source to lower the off-target toxicities of chemotherapeutic agents and maximize the patient benefits. This is a crucial approach for a more effective treatment and prevention of disease. Precision-medicine methods are based on the selection of suitable biomarkers to envision the effectiveness of targeted therapy in a specific group of patients. Several druggable mutations have been identified in breast cancer patients. Current improvements in omics technologies have focused on more precise strategies for precision therapy. The development of next-generation sequencing technologies has raised hopes for precision-medicine treatment strategies in breast cancer (BC) and triple-negative breast cancer (TNBC). Targeted therapies utilizing immune checkpoint inhibitors (ICIs), epidermal growth factor receptor inhibitor (EGFRi), poly(ADP-ribose) polymerase inhibitor (PARPi), antibody–drug conjugates (ADCs), oncolytic viruses (OVs), glucose transporter-1 inhibitor (GLUT1i), and targeting signaling pathways are potential treatment approaches for BC and TNBC. This review emphasizes the recent progress made with the precision-medicine therapy of metastatic breast cancer and TNBC.

The innovative development of nanomedicine has promised effective treatment options compared to the standard therapeutics for cancer therapy. However, the efficiency of EPR-targeted nanodrugs is not always pleasing as it is strongly prejudiced by the heterogeneity of the enhanced permeability and retention effect (EPR). Targeting the dynamics of the EPR effect and improvement of the therapeutic effects of nanotherapeutics by using EPR enhancers is a vital approach to developing cancer therapy. Inadequate data on the efficacy of EPR in humans hampers the clinical translation of cancer drugs. Molecular targeting, physical amendment, or physiological renovation of the tumor microenvironment (TME) are crucial approaches for improving the EPR effect. Advanced imaging technologies for the visualization of EPR-induced nanomedicine distribution in tumors, and the use of better animal models, are necessary to enhance the EPR effect. This review discusses strategies to enhance EPR effect-based drug delivery approaches for cancer therapy and imaging technologies for the diagnosis of EPR effects. The effort of studying the EPR effect is beneficial, as some of the advanced nanomedicine-based EPR-enhancing approaches are currently undergoing clinical trials, which may be helpful to improve EPR-induced drug delivery and translation to clinics.

Background: Checklists of zoological groups are useful to document species names in a specific area or even worldwide. They serve for various purposes, including ecological studies, conservation reports, policy and decision-making, and species identification. Phlebotomine sand flies (Diptera, Psychodidae) are the vectors of pathogens such as Leishmania, Bartonella and some arboviruses (Toscana, Naples, Sicily), and checklists for sand flies have primarily been published mainly for a state, department, or country. A checklist for American sand flies was published in 2017, but, until then, no effort has been made to compile a comprehensive list of species worldwide. The present study aims to fill this gap of knowledge. Methods: The present checklist is provided based on a literature overview and biological collections records and includes unpublished data from the authors. The species are presented according to the classification, then alphabetically by Eastern and Western Hemispheres. Distribution by country and type locality of each species are provided. Discussions on the taxonomic status or occurrence of each species are provided when needed. Results: A total of 23 genera in the Western Hemisphere, formerly the New World (Bichromomyia, Brumptomyia, Deanemyia, Dampfomyia, Edentomyia, Evandromyia, Expapillata, Hertigia, Lutzomyia, Martinsmyia, Micropygomyia, Migonemyia, Nyssomyia, Oligodontomyia, Pintomyia, Pressatia, Psathyromyia, Psychodopygus, Sciopemyia, Trichophoromyia, Trichopygomyia, Viannamyia, and Warileya) and 17 genera in the Eastern Hemisphere, formerly the Old World (Australophlebotomus, Chinius, Demeillonius, Grassomyia, Idiophlebotomus, Libanophlebotomus, Libanophlebotomites, Mesophlebotomites, Paleomyia, Parvidens, Phlebotoiella, Phlebotomiella, Phlebotomites, Phlebotomus, Sergentomyia, Spelaeomyia, Spelaeophlebotomus), including the fossil species, are listed herein. The updated list, excluding nomina dubia/species inquirenda includes 1063 sand fly species, with 549 and 514 species for New World and Old World, respectively. Only New Zealand and the Pacific Islands (excluding New Caledonia) do not record the presence of sand flies. The dataset for this study is publicly available in the SiBBr and GBIF. Conclusions: This is the first detailed list of valid names of phlebotomine sand flies worldwide, including records from each country where they have been documented. Graphical

Dendrimers comprise a specific group of macromolecules, which combine structural properties of both single molecules and long expanded polymers. The three-dimensional form of dendrimers and the extensive possibilities for use of additional substrates for their construction creates a multivalent potential and a wide possibility for medical, diagnostic and environmental purposes. Depending on their composition and structure, dendrimers have been of interest in many fields of science, ranging from chemistry, biotechnology to biochemical applications. These compounds have found wide application from the production of catalysts for their use as antibacterial, antifungal and antiviral agents. Of particular interest are peptide dendrimers as a medium for transport of therapeutic substances: synthetic vaccines against parasites, bacteria and viruses, contrast agents used in MRI, antibodies and genetic material. This review focuses on the description of the current classes of dendrimers, the methodology for their synthesis and briefly drawbacks of their properties and their use as potential therapies against infectious diseases.